Results 221 to 230 of about 186,638 (392)

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj   +6 more
wiley   +1 more source

What causes alopecia areata?

open access: green, 2013
Kevin J. McElwee   +16 more
openalex   +2 more sources

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz   +8 more
wiley   +1 more source

The neglected majority: Inverse relationship between prevalence and global research activity of 15 dermatological diseases

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Oliver Brandt   +3 more
wiley   +1 more source

Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To evaluate the effect of erenumab treatment beyond monthly migraine days in patients with high‐frequency episodic migraine who did not respond to at least one previous migraine preventive treatment. Background Reduction in monthly migraine days has been the efficacy standard for migraine preventive treatments; however, it does not ...
Gabriel Paiva da Silva Lima   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy